Newsletters

Novartis-Propeller near commercial launch. 5 biz models for MSK.

5.08.20

9 min. Read

Roche VR autism DTx. Pear pre-FDA launch. Welldoc reunion.

5.01.20

6 min. Read

Akili launches pre-FDA. Korea OKs Samsung BP app.

4.24.20

3 min. Read

Analysis: FDA’s new guidance for digital therapeutics

4.17.20

10 min. Read

Livongo: 10 percent utilization uptick. $215M RWE acquisition.

4.10.20

6 min. Read

AstraZeneca’s digital health strategy. Pear and Cognoa studies.

4.03.20

7 min. Read

Orexo prices DTx at $600 to $1,000. Pear: $1,000 to $1,600.

3.27.20

5 min. Read

Genentech-Roche VR for autism. FDA’s new remote monitoring waiver.

3.20.20

7 min. Read

Verily paid Sanofi $122M. ResMed MitiGait. Happify Kopa.

3.12.20

6 min. Read

RCT shows no effect for AI coach. Livongo ups enrollment rate.

3.06.20

8 min. Read